We are live on ! Find out more
LMAT icon

LeMaitre Vascular

80.98 USD
+1.78
2.25%
At close Updated Sep 22, 4:00 PM EDT
Pre-market
After hours
80.98
0.00
0%
1 day
2.25%
5 days
1.82%
1 month
1.28%
3 months
-8.61%
6 months
-24.92%
Year to date
1.01%
1 year
-12.25%
5 years
46.81%
10 years
293.49%
 

About: LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.

Employees: 655

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 33.3%
Neutral 58.3%
Negative 8.3%
Positive
Zacks Investment Research
20 days ago
PAHC or LMAT: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks is more attractive to value investors?
PAHC or LMAT: Which Is the Better Value Stock Right Now?
Neutral
GlobeNewsWire
26 days ago
LeMaitre to Participate at Upcoming Investor Conferences in September
BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
LeMaitre to Participate at Upcoming Investor Conferences in September
Neutral
Seeking Alpha
1 month ago
Dividend Champion, Contender, And Challenger Highlights: Week August 16
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Dividend Champion, Contender, And Challenger Highlights: Week August 16
Positive
Zacks Investment Research
1 month ago
GEHC or LMAT: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
GEHC or LMAT: Which Is the Better Value Stock Right Now?
Positive
Seeking Alpha
1 month ago
LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut
LeMaitre Vascular remains a Buy after a 31% pullback, though I have trimmed my price target to $95-$100 for year-end 2027. The Q2 2026 miss was tied to currency, export blockages, and tissue shortages. Not underlying demand. Organic sales grew 10%, and margins hit record highs. Artegraft, now 21% of sales, is LMAT's largest and fastest-growing product. It is the main factor behind margin expansion and international growth prospects.
LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut
Neutral
GlobeNewsWire
1 month ago
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
BURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will hold investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026.
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Neutral
Seeking Alpha
1 month ago
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
Neutral
MarketBeat
1 month ago
LeMaitre Vascular Q2 Earnings Call Highlights
LeMaitre Vascular NASDAQ: LMAT reported second-quarter 2026 results marked by 10% organic revenue growth, record operating income and continued expansion of its Artegraft product line, while foreign exchange, Middle East export delays and cardiac allograft supply constraints weighed on sales relative to management's expectations.
LeMaitre Vascular Q2 Earnings Call Highlights
Negative
Zacks Investment Research
1 month ago
LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Lag Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.74 per share, missing the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.6 per share a year ago.
LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Lag Estimates
Neutral
GlobeNewsWire
1 month ago
LeMaitre Q2 2026 Financial Results
BURLINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.
LeMaitre Q2 2026 Financial Results
Price charts implemented using Lightweight Charts™